Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study

British Journal of Haematology
Takashi IshidaRyuzo Ueda

Abstract

This multicentre, randomized, phase II study was conducted to examine whether the addition of mogamulizumab, a humanized anti-CC chemokine receptor 4 antibody, to mLSG15, a dose-intensified chemotherapy, further increases efficacy without compromising safety of patients with newly diagnosed aggressive adult T-cell leukaemia-lymphoma (ATL). Patients were assigned 1:1 to receive mLSG15 plus mogamulizumab or mLSG15 alone. The primary endpoint was the complete response rate (%CR); secondary endpoints included the overall response rate (ORR) and safety. The %CR and ORR in the mLSG15-plus-mogamulizumab arm (n = 29) were 52% [95% confidence interval (CI), 33-71%] and 86%, respectively; the corresponding values in the mLSG15 arm (n = 24) were 33% (95% CI, 16-55%) and 75%, respectively. Grade ≥ 3 treatment-emergent adverse events, including anaemia, thrombocytopenia, lymphopenia, leucopenia and decreased appetite, were observed more frequently (≥10% difference) in the mLSG15-plus-mogamulizumab arm. Several adverse events, including skin disorders, cytomegalovirus infection, pyrexia, hyperglycaemia and interstitial lung disease, were observed only in the mLSG15-plus-mogamulizumab arm. Although the combination strategy showed a potentiall...Continue Reading

References

Aug 26, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Takashi IshidaRyuzo Ueda
Feb 6, 2007·International Journal of Cancer. Journal International Du Cancer·Hiroki YanoRyuzo Ueda
Mar 27, 2007·Nature Reviews. Cancer·Masao Matsuoka, Kuan-Teh Jeang
Oct 31, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kunihiro TsukasakiUNKNOWN Japan Clinical Oncology Group Study JCOG9801
Dec 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kunihiro TsukasakiToshiki Watanabe
Jan 2, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Masao NakagawaMasao Seto
Feb 18, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Toshihiko IshiiRyuzo Ueda
Feb 24, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kazuhito YamamotoRyuzo Ueda
Nov 4, 2010·Cancer Science·Takashi Ishida, Ryuzo Ueda
Jul 28, 2011·Expert Review of Clinical Immunology·Jocea M R Michels-van AmelsfortLeonie S Taams
Jan 10, 2012·The Lancet Oncology·Joannes F M JacobsGosse J Adema
Feb 9, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Takashi IshidaRyuzo Ueda
Sep 14, 2012·Frontiers in Microbiology·Masako IwanagaKazunari Yamaguchi
Oct 16, 2013·Proceedings of the National Academy of Sciences of the United States of America·Daisuke SugiyamaShimon Sakaguchi
Mar 13, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michinori OguraRyuzo Ueda

❮ Previous
Next ❯

Citations

Dec 15, 2015·Expert Review of Molecular Diagnostics·Rumiko Shimazawa, Masayuki Ikeda
Oct 5, 2015·Current Hematologic Malignancy Reports·Nathanael G Bailey, Kojo S J Elenitoba-Johnson
Jun 13, 2016·Cancer Chemotherapy and Pharmacology·Michinori OguraAtae Utsunomiya
Mar 22, 2016·Journal of Hepato-biliary-pancreatic Sciences·Tomoharu YoshizumiYoshihiko Maehara
May 26, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Takeshi SugioKoichi Akashi
Sep 13, 2016·Bone Marrow Transplantation·E H PhillipsK Cwynarski
Mar 8, 2016·The Lancet. Haematology·Alison J Moskowitz
Oct 12, 2016·Clinical Lymphoma, Myeloma & Leukemia·Satoshi IyamaMitsutoshi Kurosawa
Oct 16, 2016·International Journal of Clinical Oncology·Helen Ma, Maher Abdul-Hay
Sep 14, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Takashi IshidaTomoko Ohtsu
Feb 6, 2017·European Journal of Haematology·Masaaki SekineKazuya Shimoda
Jun 8, 2017·Hematological Oncology·Shinichi Makita, Kensei Tobinai
Jun 9, 2017·Journal of Clinical and Experimental Hematopathology : JCEH·Hiroo Katsuya, Kenji Ishitsuka
Mar 16, 2018·The Journal of Biological Chemistry·Mathew A CherianDaniel Rauch
Sep 2, 2018·Hematological Oncology·Koji KatoUNKNOWN ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation
Jan 19, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lucy B CookToshiki Watanabe
Jan 19, 2019·Expert Opinion on Biological Therapy·Yuta ItoKensei Tobinai
Aug 9, 2019·Journal of Clinical and Experimental Hematopathology : JCEH·Yosuke NakayaTakahisa Yamane
Dec 17, 2019·Journal of Clinical Pharmacology·Mayumi MukaiDouglas Greene

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry

Clinical Trials Mentioned

NCT01192984
NCT01611142
NCT01728805

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Related Papers

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Mian XieQi Zhan Lin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Kazuhito YamamotoRyuzo Ueda
© 2022 Meta ULC. All rights reserved